MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,765.36
-0.47%
NASDAQ 100
$30,725.81
-1.39%
DOW JONES
$51,232.00
+0.10%
NASDAQ Composite
$27,193.34
-1.25%
RUSSELL 2000
$2,775.70
-0.05%
CBOE VIX
$15.41
+2.19%
Sector Heatmap
Technology-1.79%
Financials+0.89%
Healthcare-0.39%
Consumer Cycl+0.31%
Consumer Staples+2.11%
Energy+2.97%
Industrials+0.33%
Materials+0.59%
Real Estate+0.69%
Utilities-0.19%
Comm Services+0.73%
RNAZ — TransCode Therapeutics, Inc. Common Stock
NasdaqTransCode Therapeutics, Inc. Common Stock
$1.71
-0.05(-2.84%)
- O
- 1.80
- H
- 1.80
- L
- 1.68
- V
- 27.83K
⏱️ End-of-day dataAs of Oct 8, 2026
Chart
About RNAZ
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJul 9, 2021
Employees12
Stock ExchangeNasdaq
Ticker SymbolRNAZ
Key Financial Statistics
| Market Cap | $26.58M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.52 - $20.99 |
| 52-Week Avg Volume | 124.9K |
| VWAP | $1.74 |
| Transactions | 390 |
| Total Recorded Bars | 1,319 days |